{
  "docId": "019de517-1302-72c9-b1b1-402f68725e8a",
  "docSlug": "8240d0b9060d59c07a4e5f5063c97322",
  "documentTitle": "Adagio Therapeutics | Results Presentation Deck | 11 slides",
  "authorId": "adagio-therapeutics",
  "authorName": "Invivyd",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 11,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 7,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de517-1302-72c9-b1b1-402f68725e8a/8",
  "deckHref": "/decks/019de517-1302-72c9-b1b1-402f68725e8a",
  "deckJsonHref": "/decks/019de517-1302-72c9-b1b1-402f68725e8a.json",
  "deckAnchorHref": "/decks/019de517-1302-72c9-b1b1-402f68725e8a#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.63,
        "w": 0.66,
        "x": 0.04,
        "y": 0.27
      },
      "kind": "chart",
      "text": "4M (e.g., early-stage kidney disease, virally-suppressed HIV); 3M (e.g., non-hematologic cancer, IBD, MS); 2M (e.g., RA, primary immunodeficiency diseases); 485K",
      "attrs": null,
      "subkind": "bubble",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4017dbb2-9ea3-4965-a613-baef1f9037d3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.28,
        "w": 0.25,
        "x": 0.72,
        "y": 0.27
      },
      "kind": "list",
      "text": "Of the estimated 485K immunocompromised people at highest risk:\n67K: stem cell transplants\n86K: solid organ transplants (liver/lung/kidney)\n332K: hematologic/lymphatic cancers",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "35d643fb-0cfd-44e9-985f-501ae130eb79",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.25,
        "x": 0.72,
        "y": 0.605
      },
      "kind": "list",
      "text": "Care for these populations is often associated with specialized centers",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9ab3e36d-44d7-470c-b831-a19ea11e8913",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.44,
        "x": 0.049,
        "y": 0.229
      },
      "kind": "paragraph",
      "text": "Estimated U.S. total addressable market (TAM)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f73d5ec9-1a53-459c-9fc4-34181dc3c252",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.79,
        "x": 0.049,
        "y": 0.943
      },
      "kind": "source-note",
      "text": "Reference: Illustrative graph and estimated market opportunity based on Invivyd-sponsored market research and internal analysis. PrEP: Pre-exposure prophylaxis; RA: rheumatoid arthritis; IBD: inflammatory bowel disease; MS: multiple sclerosis; HIV: human immunodeficiency virus; HCP: Health care professional",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4a7cbd6c-e127-4ef7-929c-408867651e78",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.901,
        "x": 0.049,
        "y": 0.065
      },
      "kind": "title",
      "text": "SIGNIFICANT MARKET OPPORTUNITY WITH >9M IMMUNOCOMPROMISED PEOPLE AT INCREASED RISK FOR SEVERE COVID-19 IN THE U.S.",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2800fba9-02cc-47cb-8aa5-929f0d721790",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 9,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "d0bf14cf-88e0-4c86-bb16-82a24eeb0889",
      "evidence": "The presentation highlights the urgent need for protection and the potential consequences of inaction",
      "position": 0,
      "objective": "What is the cost of not protecting immunocompromised individuals from COVID-19?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}